Blue Owl Capital Holdings LP Makes New $2.20 Million Investment in Arcellx, Inc. $ACLX

Blue Owl Capital Holdings LP purchased a new position in shares of Arcellx, Inc. (NASDAQ:ACLX) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 26,823 shares of the company’s stock, valued at approximately $2,202,000.

A number of other hedge funds have also made changes to their positions in the stock. MAI Capital Management bought a new position in shares of Arcellx in the 3rd quarter valued at approximately $26,000. CWM LLC boosted its position in Arcellx by 267.0% during the third quarter. CWM LLC now owns 345 shares of the company’s stock worth $28,000 after purchasing an additional 251 shares during the period. State of Wyoming acquired a new position in Arcellx during the second quarter valued at approximately $28,000. Ramirez Asset Management Inc. acquired a new position in Arcellx during the third quarter valued at approximately $41,000. Finally, PNC Financial Services Group Inc. raised its position in shares of Arcellx by 183.4% in the second quarter. PNC Financial Services Group Inc. now owns 751 shares of the company’s stock valued at $49,000 after purchasing an additional 486 shares during the period. Institutional investors and hedge funds own 96.03% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ACLX. Stifel Nicolaus restated a “hold” rating and issued a $115.00 price objective (down from $127.00) on shares of Arcellx in a research note on Monday, February 23rd. Needham & Company LLC downgraded shares of Arcellx from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Robert W. Baird reiterated a “neutral” rating and issued a $115.00 target price (up from $106.00) on shares of Arcellx in a research note on Monday, February 23rd. TD Cowen downgraded shares of Arcellx from a “strong-buy” rating to a “hold” rating in a report on Monday. Finally, Leerink Partners reissued a “market perform” rating and set a $115.00 target price on shares of Arcellx in a research report on Tuesday, February 24th. One research analyst has rated the stock with a Buy rating, seventeen have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Arcellx has an average rating of “Hold” and an average price target of $111.87.

Arcellx Stock Down 0.0%

Shares of NASDAQ ACLX opened at $114.33 on Friday. The business’s 50 day moving average is $76.67 and its two-hundred day moving average is $77.68. The company has a market cap of $6.69 billion, a P/E ratio of -28.09 and a beta of 0.23. Arcellx, Inc. has a 12 month low of $47.86 and a 12 month high of $114.80.

Arcellx (NASDAQ:ACLX) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($1.01) EPS for the quarter, hitting analysts’ consensus estimates of ($1.01). Arcellx had a negative return on equity of 55.42% and a negative net margin of 1,027.26%.The company had revenue of $1.65 million during the quarter, compared to analyst estimates of $13.40 million. Sell-side analysts expect that Arcellx, Inc. will post -1.58 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Rami Elghandour sold 89,916 shares of the company’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $113.92, for a total transaction of $10,243,230.72. Following the completion of the transaction, the insider directly owned 276,051 shares in the company, valued at $31,447,729.92. This represents a 24.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Christopher Heery sold 7,437 shares of the stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $65.51, for a total transaction of $487,197.87. Following the completion of the sale, the insider directly owned 29,631 shares of the company’s stock, valued at approximately $1,941,126.81. This trade represents a 20.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 109,366 shares of company stock worth $11,526,708 in the last ninety days. 8.35% of the stock is currently owned by insiders.

About Arcellx

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.